alpha-aminopyridine has been researched along with Kahler Disease in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, E; Hiki, Y; Hotta, K; Ishii-Karakasa, I; Iwase, H; Kobayashi, Y | 1 |
| Gao, J; Geng, X; Liu, L; Wang, T; Zhang, J | 1 |
| Cai, Z; Cao, L; Cao, W; Chen, J; Chen, Q; Gu, H; He, J; Hou, Y; Li, Y; Liu, Y; Qu, J; Zhang, E | 1 |
| Chen, X; Dong, Y; Feng, J; Shu, M; Tang, H; Xu, L | 1 |
| Moore, DC; Muslimani, A; Nelson, V | 1 |
| Chen, GH; Fu, CC; Liu, W; Liu, Y; Wu, DP; Xie, Y; Xu, Y; Yan, LZ; Yan, S; Yao, WQ | 1 |
| Hatta, Y; Hino, H; Hiramoto, M; Iriyama, N; Miyazawa, K; Moriya, S; Takei, M | 1 |
| Cai, Z; Chen, J; Chen, Q; Gu, H; Guo, X; He, D; He, H; He, J; Huang, X; Wang, G; Yan, H; Yang, Y; Yi, Q; Zhang, E; Zhao, Y | 1 |
| Fu, R; Jing, Q; Li, Y; Liu, Z; Mi, F; Wang, Y; Xiang, C | 1 |
| Bashash, D; Kazemi, A; Momeny, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A | 1 |
| Azab, AK; Azab, F; Buggio, M; de la Puente, P; Fiala, M; Muz, B; Pachter, JA; Padval, MV; Vij, R; Weaver, DT | 1 |
| Cronstein, BN; He, W; Mazumder, A; Wilder, T | 1 |
| Azab, AK; Azab, F; Ghobrial, IM; Glavey, SV; Manier, S; Mishima, Y; Moschetta, M; Roccaro, AM; Sacco, A; Sahin, I; Tsang, B; Zhang, Y | 1 |
| Aljawai, Y; Anderson, KC; Ghobrial, IM; Glavey, S; Huynh, D; Maiso, P; Manier, S; Mishima, Y; Moschetta, M; Munshi, NC; Pachter, J; Reagan, M; Ring, JE; Roccaro, AM; Sacco, A; Sahin, I; Tai, YT; Tam, WF; Xu, Q; Zhang, W; Zhang, Y | 1 |
| Fitter, S; Gan, ZY; Martin, SK; To, LB; Zannettino, AC | 1 |
| Chen, XQ; Dong, Y; Gao, GX; Gong, X; Shu, MM; Tang, HL; Xin, XL; Xu, L | 1 |
| Cao, B; Chen, G; Han, K; Kong, Y; Mao, X; Tang, X; Xu, X; Xu, Z; Zeng, Y; Zhang, Z | 1 |
| Cui, YS; Fang, BJ; Liu, LN; Liu, YZ; Song, YP; Wang, DY | 1 |
| Chen, Y; Tong, J; Wang, Y; Wu, Y; Xiang, R; Xu, W; Yan, H; Yu, W; Zhang, N | 1 |
| Friedman, JM; Hasegawa, Y; Iwami, T; Kawabe, T; Kufe, DW; Saito, N; Sakakibara, K; Sato, T; Suzuki, A; Vonhoff, DD | 1 |
| Baladandayuthapani, V; He, J; Hong, S; Kwak, LW; Lan, Y; Li, H; Lin, H; Liu, Z; Lu, Y; Qian, J; Shah, J; Thomas, S; Yang, J; Yi, Q; Zhang, L; Zheng, Y | 1 |
| Berghuis, AM; De Schutter, JW; Huang, XF; Lin, YS; Park, J; Sebag, M; Tsantrizos, YS | 1 |
22 other study(ies) available for alpha-aminopyridine and Kahler Disease
| Article | Year |
|---|---|
Analysis of glycoform of O-glycan from human myeloma immunoglobulin A1 by gas-phase hydrazinolysis following pyridylamination of oligosaccharides.
Topics: alpha-Fetoproteins; Amination; Aminopyridines; Animals; Carbohydrate Sequence; Cattle; Chromatography, Gas; Chromatography, High Pressure Liquid; Humans; Hydrazines; Immunoglobulins; Molecular Sequence Data; Multiple Myeloma; Myeloma Proteins; Oligosaccharides; Polysaccharides | 1992 |
Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-Quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth.
Topics: Aminopyridines; DNA; Fluoroquinolones; Humans; Indans; Molecular Docking Simulation; Multiple Myeloma; Naphthyridines; Oxadiazoles; Quinolones; RNA, Messenger | 2022 |
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; DNA Methylation; Humans; Mice; Multiple Myeloma; Neoplasm Recurrence, Local; Sulfonamides | 2022 |
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Autophagy; Benzamides; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Epigenomics; Female; Histone Deacetylases; Humans; Mice; Mice, Nude; Microscopy, Electron, Transmission; Multiple Myeloma | 2020 |
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Triazines | 2021 |
[The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].
Topics: Aminopyridines; Apoptosis; Benzamides; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pharmaceutical Preparations | 2021 |
The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Topics: Aminopyridines; Apoptosis; Autophagy; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Multiple Myeloma; Protein Kinase Inhibitors | 2018 |
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Bone Diseases; Bone Resorption; Cell Cycle Checkpoints; Cell Line, Tumor; Cells, Cultured; Histone Deacetylase Inhibitors; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts | 2018 |
The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
Topics: Acetylation; Aminopyridines; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Signal Transduction; Time Factors; Valproic Acid | 2019 |
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; M Phase Cell Cycle Checkpoints; Morpholines; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Tumor Protein p73 | 2019 |
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Topics: Aminopyridines; Benzamides; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Hypoxia; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Sulfonamides; Tumor Cells, Cultured | 2019 |
Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.
Topics: Acetamides; Adenosine; Aminopyridines; Animals; Bone and Bones; Cell Differentiation; Cells, Cultured; Dipyridamole; Female; Humans; Mice; Mice, Knockout; Multiple Myeloma; Osteocalcin; Osteoclasts; Purinergic P1 Receptor Agonists; Purines; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Reverse Transcriptase Polymerase Chain Reaction; Xanthines | 2013 |
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line; Cell Line, Tumor; Chemotaxis; Coculture Techniques; Drug Screening Assays, Antitumor; Female; Fibronectins; Humans; Mesenchymal Stem Cells; Mice; Mice, SCID; Morpholines; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Waldenstrom Macroglobulinemia; Xenograft Model Antitumor Assays | 2014 |
Pyk2 promotes tumor progression in multiple myeloma.
Topics: Aminopyridines; Animals; beta Catenin; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Progression; Female; Focal Adhesion Kinase 2; Gene Expression Regulation, Enzymologic; Green Fluorescent Proteins; HEK293 Cells; Humans; Immunoblotting; Luminescent Measurements; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survival Analysis; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2014 |
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Bone Diseases; Cell Cycle; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, Inbred C57BL; Morpholines; Multiple Myeloma; Osteoclasts; Osteolysis; Phosphoinositide-3 Kinase Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
[Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response].
Topics: Aminopyridines; Apoptosis; Benzamides; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Damage; Down-Regulation; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Morpholines; Multiple Myeloma; Pyrones | 2015 |
SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulation; Female; HEK293 Cells; Humans; Hydrazones; Lysosomes; Mechanistic Target of Rapamycin Complex 1; Mice, Nude; Multiple Myeloma; Multiprotein Complexes; Proteasome Endopeptidase Complex; Regulatory-Associated Protein of mTOR; Signal Transduction; Small Molecule Libraries; TOR Serine-Threonine Kinases | 2015 |
[Successful treatment of one case with relapsed refractory multiple myeloma by chidamide in combination with bortezomib and dexamethasone].
Topics: Aminopyridines; Benzamides; Bortezomib; Dexamethasone; Humans; Multiple Myeloma | 2016 |
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Topics: Aminopyridines; Animals; Apoptosis; Bortezomib; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Mice; Morpholines; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Topics: Active Transport, Cell Nucleus; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Karyopherins; Male; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Pyrrolidinones; Receptors, Cytoplasmic and Nuclear; Ubiquitin | 2011 |
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dexamethasone; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, SCID; Morpholines; Multiple Myeloma | 2012 |
Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
Topics: Aminopyridines; Aniline Compounds; Antineoplastic Agents; Apoptosis; Catalytic Domain; Cell Survival; Crystallography, X-Ray; Diphosphonates; Drug Design; Extracellular Signal-Regulated MAP Kinases; Geranyltranstransferase; Hemiterpenes; Humans; Models, Molecular; Multiple Myeloma; Organophosphorus Compounds; Phosphorylation; Protein Conformation; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |